RVTY vs DHR vs A Stock Comparison

Revvity, Danaher and Agilent Technologies Prices as of Oct 26, 2026 Peers: Industry group
RVTY Revvity, Inc.
$160.32 +6.1% 1M +62.1% 1Y
Market cap
$18.15B
P/E
76.4x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win
DHR Danaher Corp /De/
$232.95 +3.7% 1M +4.5% 1Y
Market cap
$164.04B
P/E
41.0x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
A Agilent Technologies, Inc.
$175.96 +1.8% 1M +18.9% 1Y
Market cap
$50.24B
P/E
34.9x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
8 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 8 of the 12 questions below (Agilent Technologies 8, Danaher 3, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRVTYDHRALeader
Larger companyMarket capitalisation $18.15B $164.04B $50.24B DHR
Cheaper on earningsLower P/E, profitable companies only 76.4x 41.0x 34.9x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 31.4x 25.6x 26.9x DHR
Faster revenue growthRevenue growth, trailing twelve months +4.1% +4.6% +8.6% A
More profitableNet margin, trailing twelve months 8.2% 15.9% 19.5% A
Better return on capitalReturn on invested capital 3.1% 5.7% 13.1% A
Less leveragedLower net debt / EBITDA 2.8x 2.9x 1.1x A
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% A
Better 1-year returnPrice return, last 12 months +62.1% +4.5% +18.9% RVTY
Better 5-year returnAnnualised price return, 5 years -1.6%/yr -5.3%/yr +2.5%/yr A
Less volatileAnnualised volatility, 1 year 39.9% 30.7% 32.4% DHR
Higher overall scoreMean of the five percentile scores vs peers 58/100 59/100 62/100 A

Percentile Scorecard

RVTYDHRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRVTYDHRA
Valuation 68 #73 of 228 67 #75 of 228 58 #97 of 228
Growth 27 #161 of 221 21 #176 of 221 36 #141 of 221
Profitability 79 #45 of 208 88 #26 of 208 91 #20 of 208
Financial Health 47 #128 of 239 46 #130 of 239 55 #108 of 239
Shareholder Returns 69 #43 of 137 76 #34 of 137 71 #40 of 137
Overall 58 59 62
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • A ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRVTYDHRASPY
1 month +6.1%+3.7%+1.8% -0.8%
3 months +48.4%+18.5%+27.6% +3.5%
6 months +84.7%+29.0%+52.2% +7.0%
Year to date +65.7%+1.8%+29.3% +12.2%
1 year +62.1%+4.5%+18.9% +13.0%
3 years +63.8%+24.0%+71.2% +86.3%
3 years, per year +17.9%+7.4%+19.6% +23.1%
5 years -7.8%-23.7%+13.3% +68.6%
5 years, per year -1.6%-5.3%+2.5% +11.0%
10 years +216.8%+199.7%+305.7% +258.0%
10 years, per year +12.2%+11.6%+15.0% +13.6%

Risk

MeasureRVTYDHRASPY
Volatility, 1Y 39.9%30.7%32.4% 12.7%
Downside volatility, 1Y 35.7%31.8%27.5% 12.7%
Beta vs S&P 500, 1Y 1.220.450.88 1.00
Return / volatility, 1Y 1.560.150.58 1.02
Max drawdown, 5Y -59.2%-50.8%-39.6% -25.4%
From 52-week high 0.0%-3.8%-1.0% -1.8%
52-week high $160.32$242.05$177.72 $779.14
52-week low $82.26$161.91$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRVTYDHRA
P/E now vs peer median 75.3xmedian 30.6x 41.0xmedian 30.6x 34.5xmedian 30.6x
P/S now vs peer median 6.1xmedian 3.0x 6.5xmedian 3.0x 6.7xmedian 3.0x
EV/EBITDA now vs peer median 25.9xmedian 17.5x 24.3xmedian 17.5x 27.1xmedian 17.5x
P/FCF now vs peer median 31.4xmedian 23.3x 30.0xmedian 23.3x 39.2xmedian 23.3x
P/B now vs peer median 2.5xmedian 2.4x 3.1xmedian 2.4x 6.7xmedian 2.4x
PEG now vs peer median -2.42median 0.87 -3.28median 0.87 3.51median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRVTYDHRA
Revenue $2.91B $25.11B $7.37B
Gross profit $1.60B $14.69B $3.97B
Operating income $358.85M $5.13B $1.64B
Net income $237.55M $4.00B $1.44B
Free cash flow $568.85M $5.47B $1.27B
R&D $215.83M $1.62B $485.00M
EPS (diluted) $2.13 $5.66 $5.09
Cash & equivalents $1.02B $4.35B $1.76B
Total debt $3.21B $26.56B $3.95B
Shares (diluted) 111.63M 707.60M 283.00M
Enterprise value $14.42B $147.85B $43.13B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRVTYDHRA
P/E 75.3x 41.0x 34.5x
P/FCF 31.4x 30.0x 39.2x
P/Operating cash flow 28.0x 24.7x 30.8x
P/S 6.1x 6.5x 6.7x
P/B 2.5x 3.1x 6.7x
P/Tangible book 3.6x 5.2x 7.7x
EV/EBITDA 25.9x 24.3x 27.1x
EV/EBIT 55.9x 36.3x 31.6x
EV/Revenue 6.9x 7.4x 7.0x
EV/FCF 35.3x 34.0x 40.9x
EV/Operating cash flow 31.4x 28.0x 32.2x
PEG (3Y EPS CAGR) -2.42 -3.28 3.51

Growth

14 metrics
MetricRVTYDHRA
Revenue growth (1Y) 4.1% 4.6% 8.6%
Revenue CAGR (3Y) 0.9% -0.5% 1.8%
Gross profit growth (1Y) 2.3% 2.6% 11.2%
Gross profit CAGR (3Y) -0.4% -0.9% 3.7%
Operating income growth (1Y) -5.5% 16.1% 13.5%
Operating income CAGR (3Y) -3.7% -7.1% 5.1%
Net income growth (1Y) -16.7% 17.3% 18.0%
Net income CAGR (3Y) -33.8% -14.3% 8.3%
EPS growth (1Y) -12.3% 19.2% 18.9%
EPS CAGR (3Y) -31.2% -12.5% 9.8%
Operating cash flow growth (1Y) 6.2% 7.6% 7.6%
Operating cash flow CAGR (3Y) 86.9% -7.6% -1.9%
Free cash flow growth (1Y) 9.5% 12.4% 16.5%
Free cash flow CAGR (3Y) 64.8% -9.0% -3.7%

Profitability

14 metrics
MetricRVTYDHRA
Gross margin 55.0% 58.5% 53.8%
EBITDA margin 26.6% 30.5% 25.9%
Operating margin 12.3% 20.4% 22.2%
Pretax margin 9.0% 19.0% 22.5%
Net margin 8.2% 15.9% 19.5%
FCF margin 19.5% 21.8% 17.2%
Operating cash flow margin 21.9% 26.4% 21.8%
Return on equity 3.3% 7.6% 19.9%
Return on assets 2.0% 4.5% 10.7%
Return on invested capital 3.1% 5.7% 13.1%
Return on capital employed 3.3% 6.4% 14.6%
Asset turnover 0.2x 0.3x 0.5x
Cash conversion (OCF / net income) 2.7x 1.7x 1.1x
Stock comp / revenue 0.8% 1.2% 1.8%

Financial Health

11 metrics
MetricRVTYDHRA
Debt / assets 26.6% 28.8% 28.3%
Debt / equity 0.4x 0.5x 0.5x
Net debt / EBITDA 2.8x 2.9x 1.1x
Debt / FCF 5.6x 4.9x 3.1x
Liabilities / assets 40.0% 43.1% 47.3%
Equity / assets 60.0% 56.9% 52.7%
Interest coverage 3.7x 17.6x 15.5x
Current ratio 1.8x 1.7x 2.1x
Quick ratio 1.4x 1.0x 1.4x
Cash ratio 0.8x 0.5x 0.8x
Altman Z-score 3.38 3.72 5.82

Shareholder Returns

7 metrics
MetricRVTYDHRA
Dividend yield 0.2% 0.7% 0.6%
Net buyback yield 2.6% 1.8% 0.6%
Shareholder yield 2.8% 2.4% 1.2%
Payout ratio (earnings) 13.4% – 19.9%
Payout ratio (FCF) 5.6% – 22.6%
Dividend growth (1Y) -6.3% – 2.1%
Dividend CAGR (3Y) -6.1% – 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRVTYDHRA
Forward P/E 31.4xFY2026 25.6xFY2026 26.9xFY2026
EPS, next fiscal year $5.10FY2026 $9.11FY2026 $6.54FY2026
EPS growth, next FY +0.8%FY2026 +16.8%FY2026 +17.0%FY2026
EPS growth, the year after +11.0% +8.0% +0.3%
Revenue, next fiscal year $2.98BFY2026 $27.01BFY2026 $7.87BFY2026
Revenue growth, next FY +4.0%FY2026 +9.9%FY2026 +15.3%FY2026
Revenue growth, the year after -2.0% -1.9% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRVTYDHRA
Held by institutions 100.0% 81.9% 92.6%
Institutions holding 545 2,115 1,122
Change in shares held, QoQ -1.3% +1.1% +3.2%
Institutions buying 301 837 599
Institutions selling 161 1,015 350
Buyers to sellers 1.87 0.82 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RVTYDHRA
RVTY 1.00 0.51 0.64
DHR 0.51 1.00 0.60
A 0.64 0.60 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RVTY, DHR and A?

Danaher (DHR) is the largest by market capitalisation: Revvity (RVTY) $18.15B, Danaher (DHR) $164.04B, Agilent Technologies (A) $50.24B.

Which stock is cheaper, RVTY, DHR and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Revvity (RVTY) 76.4x, Danaher (DHR) 41.0x, Agilent Technologies (A) 34.9x). On next year's consensus earnings, Danaher (DHR) is cheapest (Revvity (RVTY) 31.4x, Danaher (DHR) 25.6x, Agilent Technologies (A) 26.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Revvity (RVTY) +4.1%, Danaher (DHR) +4.6%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Revvity (RVTY) 8.2%, Danaher (DHR) 15.9%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Revvity (RVTY) 3.1%, Danaher (DHR) 5.7%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Revvity (RVTY) +62.1%, Danaher (DHR) +4.5%, Agilent Technologies (A) +18.9%. Over five years, Agilent Technologies (A) compounded fastest (Revvity (RVTY) -1.6%/yr, Danaher (DHR) -5.3%/yr, Agilent Technologies (A) +2.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Revvity (RVTY) 0.00%, Danaher (DHR) 0.00%, Agilent Technologies (A) 0.01%. Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Revvity (RVTY) 39.9%, Danaher (DHR) 30.7%, Agilent Technologies (A) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RVTY, DHR and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.